576 related articles for article (PubMed ID: 28760303)
1. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
2. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
3. Targets for Ibrutinib Beyond B Cell Malignancies.
Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
[TBL] [Abstract][Full Text] [Related]
4. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
6. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
7. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
8. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for treatment of chronic lymphocytic leukemia.
Vela CM; McBride A; Jaglowski SM; Andritsos LA
Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
O'Brien S; Furman RR; Coutre SE; Sharman JP; Burger JA; Blum KA; Grant B; Richards DA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Izumi R; Hamdy A; Chang BY; Graef T; Clow F; Buggy JJ; James DF; Byrd JC
Lancet Oncol; 2014 Jan; 15(1):48-58. PubMed ID: 24332241
[TBL] [Abstract][Full Text] [Related]
14. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Brown JR; Barrientos JC; Barr PM; Flinn IW; Burger JA; Tran A; Clow F; James DF; Graef T; Friedberg JW; Rai K; O'Brien S
Blood; 2015 May; 125(19):2915-22. PubMed ID: 25755291
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
[TBL] [Abstract][Full Text] [Related]
16. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Sukbuntherng J; Chang BY; Clow F; Hedrick E; Buggy JJ; James DF; O'Brien S
N Engl J Med; 2013 Jul; 369(1):32-42. PubMed ID: 23782158
[TBL] [Abstract][Full Text] [Related]
17. Management of adverse effects/toxicity of ibrutinib.
Paydas S
Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
[TBL] [Abstract][Full Text] [Related]
18. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]